Market Place
Sourcing Support
Eisai Files NDA for Subcutaneous LEQEMBI in Early AD in Japan
27 Nov 2025 //
GLOBENEWSWIRE
Eisai Files sBLA with FDA for LEQEMBI in Early Alzheimer Diseases
25 Nov 2025 //
PR NEWSWIRE
Biogen & Dayra Partner On Oral Macrocyclic Peptide Discovery
25 Nov 2025 //
GLOBENEWSWIRE
Biogen`s Leqembi Rises After Novo GLP-1 Fails In Alzheimer`s
24 Nov 2025 //
BIOSPACE
Versant Ventures Launches Biogen-Backed Dayra Therapeutics
24 Nov 2025 //
BUSINESSWIRE
Biogen Returns To Its Roots With A West Coast Immunology Outpost
18 Nov 2025 //
FIERCE BIOTECH
Stoke, Biogen Publish 2-Year Dravet Data
18 Nov 2025 //
BUSINESSWIRE
Nusinersen High Dose Regimen Gets Positive CHMP Opinion
17 Nov 2025 //
GLOBENEWSWIRE
Biogen Completes Acquisition Of Alcyone Therapeutics
15 Nov 2025 //
GLOBENEWSWIRE
UK Approves Leqembi Iv for Early Alzheimer`s Disease
13 Nov 2025 //
GLOBENEWSWIRE
Biogen Ticks Up Sales Outlook Again As MS Franchise Holds Strong
30 Oct 2025 //
FIERCE PHARMA
Sales of Leqembi Totaled 18 Billion Yen in Third Quarter 2025
30 Oct 2025 //
PR NEWSWIRE
Samsung Bioepis to Launch Byooviz in Europe in January 2026
29 Oct 2025 //
BUSINESSWIRE
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Health Canada Authorizes “LEQEMBI” For Early Alzheimer`s Disease
26 Oct 2025 //
GLOBENEWSWIRE
Biogen Licenses Vanqua Bio`s Immune Disorder Drug For $1.06B
25 Oct 2025 //
REUTERS
Biogen To Unveil More Phase 3 Dapirolizumab Pegol Data For Lupus
22 Oct 2025 //
GLOBENEWSWIRE
Leqembi Iqlik Autoinjector Honored in Time`s best Inventions List
14 Oct 2025 //
PR NEWSWIRE
Stoke Therapeutics, Biogen Unveil Zorevunersen Data at Meeting
09 Oct 2025 //
BUSINESSWIRE
Genentech Awarded $124M In Cabilly Patent Dispute With Biogen
06 Oct 2025 //
FIERCE PHARMA
Biogen-Backed Web Series Gets Bill Nye Back In The Lab
30 Sep 2025 //
FIERCE PHARMA
Biogen Shuffles 20 Staff After Ending AAV Work
29 Sep 2025 //
BIOSPACE
China Approves `leqembi` Maintenance Dosing For Early Alzheimer
28 Sep 2025 //
GLOBENEWSWIRE
Biogen Discontinues All Aav Gene Therapy Work
26 Sep 2025 //
FIERCE BIOTECH
Lecanemab Approval For Alzheimer`s Treatment In Australia
24 Sep 2025 //
GLOBENEWSWIRE
FDA Rejects Biogen`s Higher Dose For Genetic Disorder Drug
24 Sep 2025 //
PRESS RELEASE
Biogen Inks $85 M Alcyone Buyout to Acquire Drug Delivery Tech
19 Sep 2025 //
FIERCE BIOTECH
Biogen Gets EU Approval for Zurzuvae for Postpartum Depression
17 Sep 2025 //
GLOBENEWSWIRE
Biogen`s `Underappreciated` Pipeline Revealed Through Lupus Study
09 Sep 2025 //
BIOSPACE
C4 Therapeutics highlight Biogen Collaboration Success
04 Sep 2025 //
GLOBENEWSWIRE
FDA Begins sBLA for Leqembi® Iqlik as Early Alzheimer`s Treatment
02 Sep 2025 //
PR NEWSWIRE
Eisai Begins Rolling sBLA for Leqembi Iqlik in Early Alzheimer
02 Sep 2025 //
GLOBENEWSWIRE
Biogen, Stoke Present Zorevunersen Data In Dravet Syndrome
02 Sep 2025 //
PHARMAWEB
Eisai Scores FDA Nod for Subcutaneous Leqembi Maintenance Dose
29 Aug 2025 //
FIERCE PHARMA
Zurzuvae First MHRA-Licensed Therapy for Post-Natal Depression
28 Aug 2025 //
PHARMAWEB
Stoke, Biogen Present Zorevunersen Data In Dravet Syndrome
25 Aug 2025 //
PHARMAWEB
First Patient Dosed in Ph 3 Biogen, Stoke Dravet Study
11 Aug 2025 //
GLOBENEWSWIRE
Biogen Boosts Sales Forecast as `New Biogen` Emerges
31 Jul 2025 //
FIERCE PHARMA
Biogen’s Leqembi Advances as CEO Eyes Pipeline Rebuild
31 Jul 2025 //
BIOSPACE
Biogen, Eisai’s Leqembi Slows Alzheimer’s Over 4-Year Treatment
31 Jul 2025 //
BIOSPACE
Four-Year LEQEMBI® Data Shows Benefit in Early Alzheimer’s
30 Jul 2025 //
PR NEWSWIRE
ZURZUVAE Gets CHMP Nod for Postpartum Depression
25 Jul 2025 //
GLOBENEWSWIRE
With $2 B Investment, Biogen Will Increase Its Presence in NC
22 Jul 2025 //
FIERCE PHARMA
Biogen to Present Alzheimer’s Research at Conference
21 Jul 2025 //
GLOBENEWSWIRE
Lecanemab Drug Discovery Wins 9th Bioindustry Award in Japan
16 Jul 2025 //
PR NEWSWIRE
Biogen, Stoke Reveal Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
GLOBENEWSWIRE
Stoke, Biogen Unveil Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
BUSINESSWIRE
Sage`s Search for Lifeline Ran Into Defiant Biogen CEO
03 Jul 2025 //
BIOSPACE
Biogen Starts Phase 3 Study of Felzartamab for Nephropathy
30 Jun 2025 //
GLOBENEWSWIRE
Nusinersen Data Highlights Biogen`s Commitment to SMA Research
27 Jun 2025 //
GLOBENEWSWIRE
Biogen to Take Spinraza Follow-Up Into Registrational Studies
25 Jun 2025 //
FIERCE BIOTECH
Ionis, Biogen Advance Salanersen Into SMA Registrational Trials
25 Jun 2025 //
BUSINESSWIRE
Biogen Advances Spinal Muscular Atrophy Asset to Phase 1 Studies
25 Jun 2025 //
GLOBENEWSWIRE
Biogen Starts Ph3 Omaveloxolone in Pediatric Friedreich Ataxia
18 Jun 2025 //
GLOBENEWSWIRE
Biogen, BMS and Novartis bag spots on Cannes Lions shortlists
16 Jun 2025 //
FIERCE PHARMA
Dapirolizumab Ph3 SLE Data Shows Less Fatigue & Disease Activity
12 Jun 2025 //
GLOBENEWSWIRE
Biogen and City Therapeutics Partner on RNAi-based Therapies
27 May 2025 //
GLOBENEWSWIRE
EU authorizes Eisai-Biogen`s drug for early Alzheimer`s treatment
16 Apr 2025 //
REUTERS
Biogen’s BIIB080 Therapy Gets FDA Fast Track for Alzheimer
02 Apr 2025 //
GLOBENEWSWIRE
Organon Acquires Tofidence, a Biosimilar to Actemra in US
01 Apr 2025 //
BUSINESSWIRE
